Alaunos Therapeutics, Inc. is a biotechnology company. The Company's obesity and metabolic disorders program is advancing ALN1003, an oral small-molecule candidate being evaluated as a potential differentiated, non-hormonal, non-incretin approach for obesity- and metabolic-disease-relevant biology. ALN1003 is a preclinical, non-incretin, oral candidate targeting metabolic dysfunction beyond weight loss that may address insulin resistance, adipose signaling, liver biology, and body composition. ALN1003 is a preclinical, oral, non-hormonal metabolic therapeutic candidate being evaluated for: obesity-related metabolic dysfunction, MASH-relevant biology, and insulin resistance. The Company is advancing a pipeline of potentially transformative therapies for pulmonary hypertension and related cardiopulmonary diseases. The Company is developing ActRII-Fc ligand traps and complementary biologics. The Company's programs include VLR199, VLR247, VLR258, VLR360 and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change
09/11/26	US$1.720	-1.15%
06/11/26	US$1.740	-5.43%
05/11/26	US$1.840	+2.22%
04/11/26	US$1.800	-3.23%
03/11/26	US$1.860	+6.29%

Delayed Quote Nasdaq

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Alaunos Therapeutics, Inc.

Company calendar

Real-time Estimate Cboe BZX 20:16:23 09/11/2026 GMT			5-day change	1st Jan Change
1.725 ^USD	-0.86%		-10.77%	-46.13%

10-16	Top Premarket Gainers	MT
10-13	Alaunos Therapeutics Enters into Agreement and Plan of Merger with Velaris Therapeutics	CI

Market Cap	4.42M 3.95M 3.63M 3.3M 6.24M 414M 6.4M 43.43M 17.31M 222M 16.59M 16.24M 699M	P/E 2024	-0.65x	P/E 2025	-1.47x
Enterprise Value	3.04M 2.71M 2.49M 2.26M 4.29M 285M 4.39M 29.82M 11.89M 152M 11.39M 11.15M 480M	EV / Sales 2024	195,938,500x	EV / Sales 2025	1,164,761,400x
Free-Float	87.59%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq	TCRT	Delayed
CBOE	TCRT	Real-time

10-16	Top Premarket Gainers	MT
10-13	Alaunos Therapeutics Enters into Agreement and Plan of Merger with Velaris Therapeutics	CI
10-13	Alaunos Therapeutics, Inc. Appoints Peter Harwin to Board of Directors	CI
10-13	Top Midday Gainers	MT
10-13	Alaunos Therapeutics, Inc. announced that it expects to receive $349.953008 million in funding	CI
10-13	Alaunos Therapeutics Completes Velaris Acquisition; Shares Surge	MT
10-12	Alaunos Therapeutics, Inc. acquired Velaris Therapeutics, Inc.	CI
10-06	Certain Warrants of Alaunos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI
10-06	Certain Stock Options of Alaunos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI
10-06	Certain Common Stock of Alaunos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI
08-14	Alaunos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	Alaunos Therapeutics Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment For Body Fat Percentage In 48-Day DIO Mouse Study	CI
05-26	Alaunos Therapeutics Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies	CI

Alaunos Therapeutics, Inc. Share Price

Stocks

TCRT

US98973P3091

Biotechnology & Medical Research

Valuation: Alaunos Therapeutics, Inc.

Chart: Alaunos Therapeutics, Inc.

Latest news: Alaunos Therapeutics, Inc.

Analysts' recommendations: Alaunos Therapeutics, Inc.

Press Releases: Alaunos Therapeutics, Inc.

News in other languages: Alaunos Therapeutics, Inc.

Quotes and Performance

Managers and Directors: Alaunos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

16/08/23	HC Wainwright Downgrades Alaunos Therapeutics to Neutral From Buy	MT
15/08/23	Laidlaw Downgrades Alaunos Therapeutics to Hold From Buy	MT
04/10/22	Wells Fargo Assumes Alaunos Therapeutics at Overweight with $3 Price Target	MT
15/07/22	Cantor Fitzgerald Assumes Alaunos Therapeutics at Overweight with $3 Price Target	MT
04/05/22	Wells Fargo Upgrades Alaunos Therapeutics to Overweight From Equalweight	MT

09-18	Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules	AQ
08-14	Ziopharm: Q2 Earnings Snapshot	AQ
06-29	Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study	AQ
05-26	Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies	AQ
05-18	Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models	AQ

30/06/15	Alibaba : Les valeurs à suivre sur les marchés américains
30/06/15	USA-Les valeurs à suivre à Wall Street

Manager	Title	Age	Since
Holger Weis CEO	Chief Executive Officer	63	01/07/2025
Ferdinand Groenewald DFI	Director of Finance/CFO	42	21/02/2025

Director	Title	Age	Since
Holger Weis CHM	Chairman	63	21/09/2023
Peter Harwin BRD	Director/Board Member	40	12/10/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
06/10/26	Holger Weis	Free	Chief Executive Officer	23,564	0.9275%
06/10/26	Jaime Vieser	Free	Director	22,669	0.8923%
06/10/26	Robert Postma	Free	Director	21,829	0.8592%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALAUNOS THERAPEUTICS, INC.	-0.86%	-10.77%	-	-	4.42M
WUXI APPTEC CO., LTD.	+2.24%	+5.83%	+58.47%	+65.65%	66.7B
ARGENX SE	+4.66%	+8.90%	+14.57%	+85.41%	56.88B
LONZA GROUP AG	-0.60%	+1.73%	+23.48%	+94.40%	56.53B
BEONE MEDICINES AG	+2.72%	+16.00%	+27.31%	+121.10%	46.49B
IQVIA HOLDINGS INC.	+2.59%	+7.96%	+30.96%	+45.39%	44.8B
REVOLUTION MEDICINES, INC.	+4.21%	+5.78%	+217.30%	+894.23%	41.59B
CELLTRION, INC.	-0.47%	+9.60%	+27.53%	+52.88%	35.35B
GENMAB A/S	+3.80%	-1.00%	+95.20%	+66.79%	33.29B
INSMED INCORPORATED	+0.22%	+4.91%	-40.25%	+389.65%	25.1B
Average	+1.89%	+2.21%	+50.51%	+201.72%	40.67B
Weighted average by Cap.	+2.31%	+4.17%	+51.34%	+180.22%

	2024	2025
Net sales	0.01 0.01 0.01 0.01 0.01 0.94 0.01 0.1 0.04 0.5 0.04 0.04 1.58	0 0 0 0 0.01 0.47 0.01 0.05 0.02 0.25 0.02 0.02 0.79
Net income	-4.68M -4.18M -3.84M -3.49M -6.61M -439M -6.77M -45.97M -18.32M -235M -17.56M -17.19M -740M	-4.18M -3.73M -3.43M -3.11M -5.9M -391M -6.05M -41.03M -16.35M -210M -15.67M -15.34M -660M
Net Debt	-1.09M -974K -896K -813K -1.54M -102M -1.58M -10.72M -4.27M -54.75M -4.09M -4.01M -172M	-1.38M -1.24M -1.14M -1.03M -1.96M -130M -2.01M -13.61M -5.42M -69.5M -5.2M -5.09M -219M